Selumetinib, a selective MEK1 inhibitor, coupled with Everolimus, can attenuate angiogenesis during renal cell carcinoma proliferation by reducing VEGF secretion, consequently enhancing antitumor activity [92]. Here, VEGFA is linked to renal cell carcinoma.